	US 12,480,952 B2
	Methods of using PD-L1 expression in treatment decisions for cancer therapy
Daniel Adams, Basking Ridge, NJ (US); and Cha-Mei Tang, Potomac, MD (US)
Assigned to CREATV MICROTECH, INC., Potomac, MD (US)
Filed by Creatv MicroTech, Inc., Potomac, MD (US)
Filed on Apr. 26, 2022, as Appl. No. 17/729,208.
Application 17/729,208 is a division of application No. 16/092,998, granted, now 11,353,459, previously published as PCT/US2017/027714, filed on Apr. 14, 2017.
Claims priority of provisional application 62/322,570, filed on Apr. 14, 2016.
Prior Publication US 2022/0252605 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 45/06 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)

CPC G01N 33/57492 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2827 (2013.01); C07K 2317/76 (2013.01); G01N 2333/70532 (2013.01)]

12 Claims

1. A method of selecting a treatment for a subject having cancer, comprising: assaying cancer associated macrophage-like cells (CAMLs) and circulating tumor cells (CTCs), and optionally one or more of epithelial to mesenchymal transition CTCs (EMTCTCs) and cancer associated vascular endothelial cells (CAVEs), isolated from a subject having cancer for PD-L1 expression, wherein when PD-L1 expression is detected, the subject is identified as a subject to receive an immune checkpoint inhibitor treatment, and wherein the immune checkpoint inhibitor is an antibody.